Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;25(6):1688-1697.
doi: 10.1111/dom.15023. Epub 2023 Mar 13.

Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system

Bruno Grassi  1 , Ana Maria Gómez  2   3 , Luis Eduardo Calliari  4 , Denise Franco  5 , Marcela Raggio  6 , Francisca Riera  1 , Matias Castro  7 , Jennifer McVean  8 , Tim van den Heuvel  9 , Arcelia Arrieta  9 , Javier Castañeda  9 , Ohad Cohen  9
Affiliations

Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system

Bruno Grassi et al. Diabetes Obes Metab. 2023 Jun.

Abstract

Aim: We studied real-world performance of MiniMed (MM) 780G system users from Argentina, Brazil, Colombia and Chile (geographical analysis), and the effect of each technology iteration of the MM system on glycaemic control (technology iteration analysis).

Materials and methods: CareLink data from August 2020 to September 2022 were extracted. Endpoints included continuous glucose monitoring metrics. For the geographical analysis, aggregated endpoints for MM780G system users were calculated. For the technology iteration analysis, MM780G system user outcomes were compared with outcomes when the same individuals were still using the MM640G or MM670G system.

Results: On average, 1025 MM780G system users from the geographical analysis were followed for 136 (SD 135) days, spent 91.5 (14.3)% in advanced hybrid closed loop, showed a glucose management indicator (GMI) of 6.7 (0.3)%, a time in range between 70 and 180 mg/dl (TIR) of 76.5 (9.0)%, and a time below range 70 mg/dl (TBR) of 2.7 (2.1)%. The percentage of users reaching targets of GMI <7%, TIR >70% and TBR <4% was 80.8%, 78.1% and 80.1%, respectively. The technology iteration analysis on users transitioning from MM640G to MM780G system (N = 381) showed 0.4% decrease in GMI (7.1% to 6.7%, p < .0001), 10.7% increase in TIR (65.9% to 76.6%, p < .0001), while TBR remained. The percentage of insulin delivered automatically increased as well (47.5%-57.7%, p < .0001). Users transitioning from MM670G system (N = 78) showed a similar but less pronounced pattern.

Conclusions: Real-world Latin American MM780G users on average showed good glucose control, achieving international targets. Glycaemic control increased with every technology iteration of the MM system, providing more automation each time.

Keywords: continuous glucose monitoring; health economics; insulin pump therapy; real-world evidence; type 1 diabetes.

PubMed Disclaimer

References

REFERENCES

    1. Holt RIG, DeVries JH, Hess-Fischl A, et al. The Management of Type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2021;44(11):2589-2625. doi:10.2337/dci21-0043
    1. Sherr JL, Schoelwer M, Dos Santos TJ, et al. ISPAD clinical practice consensus guidelines 2022: diabetes technologies: insulin delivery. Pediatr Diabetes. 2022;23(8):1406-1431. doi:10.1111/pedi.13421
    1. American Diabetes Association Professional Practice Committee. 7. Diabetes technology: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S97-S112. doi:10.2337/dc22-S007
    1. Carlson AL, Sherr JL, Shulman DI, et al. Safety and glycemic outcomes during the MiniMed advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2022;24(3):178-189. doi:10.1089/dia.2021.0319
    1. Choudhary P, Kolassa R, Keuthage W, et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diabetes Endocrinol. 2022;10(10):720-731. doi:10.1016/S2213-8587(22)00212-1

Publication types

LinkOut - more resources